Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
ACTIDIL vs CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
5 mg or 10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces.
Category C
Category A/B
Antihistamine
Antihistamine